🇺🇸 FDA
Patent

US 8580768

Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61KA61K9/0019A61K9/2018

Quick answer

US patent 8580768 (Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K9/0019, A61K9/2018, A61K9/2059, A61K9/4866